Department of Obstetrics and Gynaecology, Medical University of Graz, Graz, Austria.
Department of Obstetrics and Gynaecology, Medical University of Graz, Graz, Austria.
J Reprod Immunol. 2021 Jun;145:103320. doi: 10.1016/j.jri.2021.103320. Epub 2021 Apr 8.
Preeclampsia still represents a life-threatening pregnancy complication, associated with severe maternal and neonatal morbidity and mortality. Low-dose Aspirin is advised to avoid preeclampsia in high-risk pregnancies worldwide. As Aspirin does not cover all women at risk, the prescription raises questions concerning optimal target population, dosage, and onset of therapy. The aim of this study was to test platelet responsiveness on Aspirin by optical aggegrometry, to gain robust biochemically assessment data of Aspirin in an obstetric cohort. 248 women at high risk for development of preeclampsia were included in the study. Aspirin-prophylaxis was administered either in 100 mg (n = 229) or 150 mg (n = 90) daily. Dosing of 100 mg Aspirin was maintained if testing revealed a sufficient platelet inhibition. If platelet inhibition was insufficient, dosage was increased to 150 mg Aspirin and re-testing was advised. 91 patients (91/229 = 39.7%) presented a sufficient inhibitory Aspirin effect at a dosage of 100 mg, but in 138 patients LTA showed an inadequate Aspirin response (138/229 = 60.3%). In 19 women 150 mg Aspirin was administered as starting dose due to new recommendations. Of all women at 150 mg Aspirin 64 did not properly respond (35.4%). The overall rate of sufficient responding women regardless the Aspirin dose was 64.6%. This study demonstrates still an insufficient inhibition of platelet aggregation in about 1/3 of women even with a dosage of 150 mg Aspirin daily, who might potentially benefit from further increase. These data show, that there is a need for further research to allow a personalized approach for individualized Aspirin therapy, maximizing the preventive benefit for mother and child.
子痫前期仍然是一种危及生命的妊娠并发症,与严重的母婴发病率和死亡率有关。全世界范围内,建议高危妊娠妇女使用低剂量阿司匹林预防子痫前期。由于阿司匹林并不能覆盖所有有风险的女性,因此处方引起了关于最佳目标人群、剂量和治疗开始时间的问题。本研究旨在通过光学聚集法检测阿司匹林对血小板的反应性,以获得产科队列中阿司匹林的稳健生化评估数据。研究纳入了 248 名有发生子痫前期风险的高危妇女。阿司匹林预防治疗方案为每日 100mg(n=229)或 150mg(n=90)。如果检测显示血小板抑制充分,则维持 100mg 阿司匹林的剂量。如果血小板抑制不足,则将剂量增加至 150mg 阿司匹林,并建议重新检测。91 名患者(91/229=39.7%)在 100mg 阿司匹林剂量下表现出足够的抑制作用,但在 138 名患者中 LTA 显示出阿司匹林反应不足(138/229=60.3%)。由于新的建议,19 名患者起始剂量为 150mg 阿司匹林。在所有接受 150mg 阿司匹林的女性中,有 64 名女性未能正确反应(35.4%)。无论阿司匹林剂量如何,足够反应的女性总比例为 64.6%。本研究表明,即使每日服用 150mg 阿司匹林,仍有 1/3 的女性血小板聚集抑制不足,可能需要进一步增加剂量。这些数据表明,需要进一步研究,以允许个体化的阿司匹林治疗方法,最大限度地提高母婴的预防效益。